経頭蓋交流電流刺激中に同時脳波記録（TACS）

Executive Industry Relevance

Concurrent tACS-EEG recording enables direct measurement of neurophysiological responses to neuromodulation, supporting target validation in CNS drug discovery. This approach provides mechanistic de-risking by linking oscillatory brain activity to cognitive processes, informing predictive confidence in early-stage programs. It addresses a critical gap in understanding the immediate biological effects of neuromodulatory interventions.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by measuring immediate electrophysiological effects of tACS on brain network oscillations.
• Operational Value: Supports biological de-risking through direct observation of neurophysiological engagement, reducing mechanistic ambiguity in target validation.

Screening & Assay Development

• Scientific Value: Provides a standardized, reproducible system for preparing validated neural interfaces to assess neuromodulator engagement.
• Operational Value: Highlights the need for high-resolution EEG systems to capture low-amplitude neural signals amid large stimulation artifacts, informing assay sensitivity requirements.

Translational & Preclinical Research

• Scientific Value: Offers a disease-relevant system to study rhythmic brain dynamics, supporting translational biomarker alignment for neuropsychiatric indications.
• Operational Value: Facilitates continuity from target engagement to functional readouts, enabling risk-adjusted advancement decisions in preclinical models.

Pipeline & Workflow Integration

This method integrates into the discovery continuum by supporting hypothesis testing in early biology, enabling quantitative neurophysiological readouts for screening, and providing mechanistic insights that inform preclinical continuity and target confidence.

• Discovery Biology: Supports pathway clarification and biological de-risking by measuring immediate neurophysiological effects of tACS on oscillatory brain activity.
• Screening: Enables assay readiness through standardized electrode preparation and impedance monitoring, ensuring reproducible neural signal acquisition.
• Analytics: Delivers quantitative dependent variable measurements (EEG amplitude, frequency, coherence) that allow comparison of neuromodulatory conditions and dose responses.
• Translational Research: Connects to preclinical continuity by modeling rhythmic brain dynamics relevant to disease states and therapeutic intervention.
• Enterprise Reuse: Establishes a reusable platform for evaluating diverse neuromodulatory compounds and stimulation parameters across CNS programs.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target engagement, reduction of mechanistic ambiguity in neuromodulator mechanisms.
• Operational Value: Standardization of electrode-scalp interface, reproducibility of EEG recordings, scalability across multiple stimulation sites.
• Strategic Value: Improved go/no-go decisions based on direct neurophysiological readouts, capital efficiency through early de-risking, reduced late-stage biological risk in CNS portfolios.
• Portfolio Impact: Risk-adjusted prioritization of neuromodulatory candidates using convergent electrophysiological and behavioral endpoints.

Implementation Considerations

• Requires expertise in electrophysiology, neuromodulation, and EEG signal processing to manage artifacts and ensure data quality.
• Necessitates EEG systems with high-resolution analog-to-digital converters to prevent saturation from tACS artifacts exceeding 100 mV near stimulation sites.
• Demands cross-team standardization of EEG gel viscosity to prevent electrode bridging while maintaining sufficient conductivity for signal acquisition.
• Involves adaptation considerations for different montages, hair types, and cortical targets to maintain consistent electrode-scalp contact.
• Includes practical limitations such as artifact contamination near stimulation sites and the need for careful gel management to avoid amplifier saturation.

Biopharma FAQs